Comparison
3 Methylglutaconic Aciduria Type 2 C0574083 vs 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Clinical comparison between 3 Methylglutaconic Aciduria Type 2 and 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 2 C0574083
Also called Barth syndrome, this genetic condition primarily affects males and impairs mitochondrial function. It causes heart muscle weakness, muscle weakness, and recurrent infections. Treatment includes cardiac care, infection prevention, and supportive therapies.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
A rare condition affecting how certain hormones are processed in the body, which can influence sexual development. Treatment may involve hormone therapy and specialist care.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 2 C0574083
0-5
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
0-16
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 2 C0574083
severe
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 2 C0574083
Chronic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 2 C0574083
No
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Same/different system
Category
3 Methylglutaconic Aciduria Type 2 C0574083
metabolic
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
endocrine
Different category
Bottom line
3-methylglutaconic-aciduria-type-2-C0574083 and 3-oxo-5-alpha-steroid-delta-4-dehydrogenase-deficiency-C0268297 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Discriminating power |
|---|---|---|---|
| Heart involvement | Cardiomyopathy or heart-muscle weakness may appear in infancy. | Primary heart disease is not described. | High |
| Infection pattern | Recurrent infections may accompany low neutrophils. | Recurrent infection is not a defining feature. | Moderate |
| Sexual development | Disordered sexual development is not the core presentation. | Hormone-processing changes may alter genital or pubertal development. | High |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 2 C0574083 when
Male infant with cardiomyopathy and weakness
This pattern fits the supplied mitochondrial phenotype better.
Moderate
Unexplained neutropenia with metabolic clues
Infection susceptibility supports specialist metabolic evaluation.
Moderate
Family history suggesting X-linked disease
Barth syndrome primarily affects males.
Moderate
Choose 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 when
Atypical genital or pubertal development
The source links this condition to hormone processing and sexual development.
Moderate
Endocrine evaluation without cardiac disease
An endocrine rather than mitochondrial pattern is more consistent.
Low
Need to assess androgen metabolism
Specialist hormone testing is more relevant than cardiac-metabolic testing.
Moderate
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 2 C0574083 | 3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297 | Interpretation |
|---|---|---|---|
| Urine organic acids | 3-Methylglutaconic acid may be elevated, but absence does not exclude disease. | No characteristic organic aciduria is established. | An abnormal metabolite result supports, but does not alone diagnose, Barth syndrome. |
| Blood count and cardiac assessment | Neutropenia and cardiomyopathy may be found. | These abnormalities are not expected from the source description. | Results require clinician correlation with genetics and examination. |
| Hormone profile and targeted genetics | Androgen-pathway abnormalities are not the primary finding. | Specialist hormone studies and gene testing may clarify the diagnosis. | Exact cutoffs are not established here and should not be inferred. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 2 C0574083
- Outcome
- Often severe and chronic, but individual outcome varies.
- Factors
- Heart function, infections, growth, and access to supportive care.
3 Oxo 5 Alpha Steroid Delta 4 Dehydrogenase Deficiency C0268297
- Outcome
- Described as moderate and chronic; long-term outcome is not fully established here.
- Factors
- Degree of hormonal effect, timing of diagnosis, and specialist treatment.
Time frame: Childhood onset is typical; lifelong follow-up may be needed.
Prognosis should be individualized; mortality and exact outcomes are not provided.
Complications comparison
| Complication | Presentation |
|---|---|
| Heart failure | Possible because of heart-muscle weakness. Not established by the supplied description. Cardiac complications need specialist monitoring when Barth syndrome is suspected. |
| Serious infection | Risk may be increased with recurrent infections. Not described as characteristic. Infection prevention is supportive, not a substitute for diagnosis. |
| Differences in sexual development | Not a core complication in the source. May occur and require endocrine and psychosocial care. Management is individualized; no treatment dose is specified. |
Patient education highlights
- HighDifferent conditions
These are separate genetic conditions affecting mitochondria or hormone processing, not interchangeable diagnoses.
- HighUrgent symptoms
Breathing difficulty, poor feeding, fainting, or serious infection needs prompt medical care.
- MediumSpecialist follow-up
Cardiology, metabolism, endocrinology, or genetics referral depends on the suspected condition.